181 related articles for article (PubMed ID: 32275806)
1. Prognostic Value of DNA Damage Response Genomic Alterations in Relapsed/Advanced Urothelial Cancer.
Yin M; Grivas P; Wang QE; Mortazavi A; Emamekhoo H; Holder SL; Drabick JJ; Woo MS; Pal S; Vasekar M; Folefac E; Clinton SK; Monk P; Joshi M
Oncologist; 2020 Aug; 25(8):680-688. PubMed ID: 32275806
[TBL] [Abstract][Full Text] [Related]
2. Alterations of DNA damage response genes correlate with response and overall survival in anti-PD-1/PD-L1-treated advanced urothelial cancer.
Joshi M; Grivas P; Mortazavi A; Monk P; Clinton SK; Sue-Ann Woo M; Holder SL; Drabick JJ; Yin M
Cancer Med; 2020 Dec; 9(24):9365-9372. PubMed ID: 33098265
[TBL] [Abstract][Full Text] [Related]
3.
Yin M; Grivas P; Emamekhoo H; Mendiratta P; Ali S; Hsu J; Vasekar M; Drabick JJ; Pal S; Joshi M
Oncotarget; 2018 Mar; 9(24):16891-16898. PubMed ID: 29682192
[TBL] [Abstract][Full Text] [Related]
4. DNA Damage Response and Repair Gene Alterations Are Associated with Improved Survival in Patients with Platinum-Treated Advanced Urothelial Carcinoma.
Teo MY; Bambury RM; Zabor EC; Jordan E; Al-Ahmadie H; Boyd ME; Bouvier N; Mullane SA; Cha EK; Roper N; Ostrovnaya I; Hyman DM; Bochner BH; Arcila ME; Solit DB; Berger MF; Bajorin DF; Bellmunt J; Iyer G; Rosenberg JE
Clin Cancer Res; 2017 Jul; 23(14):3610-3618. PubMed ID: 28137924
[No Abstract] [Full Text] [Related]
5. Patient-Level DNA Damage and Repair Pathway Profiles and Prognosis After Prostatectomy for High-Risk Prostate Cancer.
Evans JR; Zhao SG; Chang SL; Tomlins SA; Erho N; Sboner A; Schiewer MJ; Spratt DE; Kothari V; Klein EA; Den RB; Dicker AP; Karnes RJ; Yu X; Nguyen PL; Rubin MA; de Bono J; Knudsen KE; Davicioni E; Feng FY
JAMA Oncol; 2016 Apr; 2(4):471-80. PubMed ID: 26746117
[TBL] [Abstract][Full Text] [Related]
6. Commentary on "DNA damage response and repair gene alterations are associated with improved survival in patients with platinum-treated advanced urothelial carcinoma.".
Teo MY; Bambury RM; Zabor EC; Jordan E; Al-Ahmadie H; Boyd ME; Bouvier N; Mullane SA; Cha EK; Roper N; Ostrovnaya I; Hyman DM; Bochner BH; Arcila ME; Solit DB; Berger MF; Bajorin DF; Bellmunt J; Iyer G; Rosenberg JE
Urol Oncol; 2018 Jul; 36(7):345-346. PubMed ID: 29859727
[TBL] [Abstract][Full Text] [Related]
7. Analysis of DNA Damage Response Gene Alterations and Tumor Mutational Burden Across 17,486 Tubular Gastrointestinal Carcinomas: Implications for Therapy.
Parikh AR; He Y; Hong TS; Corcoran RB; Clark JW; Ryan DP; Zou L; Ting DT; Catenacci DV; Chao J; Fakih M; Klempner SJ; Ross JS; Frampton GM; Miller VA; Ali SM; Schrock AB
Oncologist; 2019 Oct; 24(10):1340-1347. PubMed ID: 31040255
[TBL] [Abstract][Full Text] [Related]
8. DNA damage repair pathway alterations in metastatic clear cell renal cell carcinoma and implications on systemic therapy.
Ged Y; Chaim JL; DiNatale RG; Knezevic A; Kotecha RR; Carlo MI; Lee CH; Foster A; Feldman DR; Teo MY; Iyer G; Chan T; Patil S; Motzer RJ; Hakimi AA; Voss MH
J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32571992
[TBL] [Abstract][Full Text] [Related]
9. RB1 and TP53 co-mutations correlate strongly with genomic biomarkers of response to immunity checkpoint inhibitors in urothelial bladder cancer.
Manzano RG; Catalan-Latorre A; Brugarolas A
BMC Cancer; 2021 Apr; 21(1):432. PubMed ID: 33879103
[TBL] [Abstract][Full Text] [Related]
10. Deleterious alterations of DNA damage response and repair genes and clinical benefit to anti-PD-1 therapy in esophageal squamous cell carcinoma.
Guo JC; Lin CC; Hsu CL; Huang TC; Kuo HY; Lin CY; Lien MY; Cheng AL; Hsu CH
Esophagus; 2022 Oct; 19(4):693-701. PubMed ID: 35816242
[TBL] [Abstract][Full Text] [Related]
11. The germline/somatic DNA damage repair gene mutations modulate the therapeutic response in Chinese patients with advanced pancreatic ductal adenocarcinoma.
Shui L; Li X; Peng Y; Tian J; Li S; He D; Li A; Tian B; Li M; Gao H; An N; Yi C; Cao D
J Transl Med; 2021 Jul; 19(1):301. PubMed ID: 34247626
[TBL] [Abstract][Full Text] [Related]
12. Differences in DNA damage repair gene mutations between left- and right-sided colorectal cancer.
Huang W; Li W; Xu N; Li H; Zhang Z; Zhang X; He T; Yao J; Xu M; He Q; Guo L; Zhang S
Cancer Med; 2023 May; 12(9):10187-10198. PubMed ID: 37096801
[TBL] [Abstract][Full Text] [Related]
13. Next-generation Sequencing of Nonmuscle Invasive Bladder Cancer Reveals Potential Biomarkers and Rational Therapeutic Targets.
Pietzak EJ; Bagrodia A; Cha EK; Drill EN; Iyer G; Isharwal S; Ostrovnaya I; Baez P; Li Q; Berger MF; Zehir A; Schultz N; Rosenberg JE; Bajorin DF; Dalbagni G; Al-Ahmadie H; Solit DB; Bochner BH
Eur Urol; 2017 Dec; 72(6):952-959. PubMed ID: 28583311
[TBL] [Abstract][Full Text] [Related]
14. Genomic characterization of response to chemoradiation in urothelial bladder cancer.
Desai NB; Scott SN; Zabor EC; Cha EK; Hreiki J; Sfakianos JP; Ramirez R; Bagrodia A; Rosenberg JE; Bajorin DF; Berger MF; Bochner BH; Zelefsky MJ; Kollmeier MA; Ostrovnaya I; Al-Ahmadie HA; Solit DB; Iyer G
Cancer; 2016 Dec; 122(23):3715-3723. PubMed ID: 27479538
[TBL] [Abstract][Full Text] [Related]
15. Mutations in DNA damage response pathways as a potential biomarker for immune checkpoint blockade efficacy: evidence from a seven-cancer immunotherapy cohort.
Zhang W; Zhang L; Jiang H; Li Y; Wang S; Wang Q
Aging (Albany NY); 2021 Nov; 13(21):24136-24154. PubMed ID: 34747718
[TBL] [Abstract][Full Text] [Related]
16. Landscape of DNA damage response gene alterations in breast cancer: A comprehensive investigation.
Jin J; Cao J; Li B; Li T; Zhang J; Cao J; Zhao M; Wang L; Wang B; Tao Z; Hu X
Cancer; 2023 Mar; 129(6):845-859. PubMed ID: 36655350
[TBL] [Abstract][Full Text] [Related]
17. Cell-Free DNA Sequencing Reveals Gene Variants in DNA Damage Repair Genes Associated with Prognosis of Prostate Cancer Patients.
Lieb V; Abdulrahman A; Weigelt K; Hauch S; Gombert M; Guzman J; Bellut L; Goebell PJ; Stöhr R; Hartmann A; Wullich B; Taubert H; Wach S
Cells; 2022 Nov; 11(22):. PubMed ID: 36429046
[TBL] [Abstract][Full Text] [Related]
18. DNA damage repair gene mutations and their association with tumor immune regulatory gene expression in muscle invasive bladder cancer subtypes.
Vidotto T; Nersesian S; Graham C; Siemens DR; Koti M
J Immunother Cancer; 2019 Jun; 7(1):148. PubMed ID: 31174611
[TBL] [Abstract][Full Text] [Related]
19. Low ATM expression and progression-free and overall survival in advanced gastric cancer patients treated with first-line XELOX chemotherapy.
Klempner SJ; Bhangoo MS; Luu HY; Kim ST; Chao J; Kim KM; Lee J
J Gastrointest Oncol; 2018 Dec; 9(6):1198-1206. PubMed ID: 30603142
[TBL] [Abstract][Full Text] [Related]
20. Alterations in DNA damage response and repair genes as potential biomarkers for immune checkpoint blockade in gastrointestinal cancer.
Wang Y; Jiao X; Li S; Chen H; Wei X; Liu C; Gong J; Zhang X; Wang X; Peng Z; Qi C; Wang Z; Wang Y; Zhuo N; Zou J; Zhang H; Li J; Shen L; Lu Z
Cancer Biol Med; 2021 Sep; 19(8):1139-49. PubMed ID: 34570439
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]